Skip to Content
  • Previous Rank316
  • Revenues ($M)$30,390
  • Revenue Percent Change-6.9%
  • Profits ($M)$13,501
  • Profits Percent Change-25.4%
  • Assets ($M)$56,977
  • Employees9,000

Gilead is known for its hepatitis C cures Sovaldi and Harvoni. But backlash to those drugs’ prices (among other problems) has contributed to the biotech giant’s 2016 slump. Gilead revenues fell nearly 7% to $30.4 billion in 2016 compared to the previous year. Some analysts have been urging the drug maker to make a major acquisition to shore up its experimental pipeline; but Gilead appears determined to invest in its own drug candidates by pumping money into R&D. And, in the meantime, it’s sitting on a massive bed of cash.

Fortune Data StoreLooking for leads, investment insights, or competitive intelligence?Get Premium Access

Company Information

CEO
John F. Milligan
Sector
Health Care
Industry
Pharmaceuticals
HQ Location
Foster City, CA
Websitehttp://www.gilead.com
Years on Global 500 List3
Employees9,000

Gilead Sciences Rank History

Key Financials (Last Fiscal Year)

($ Millions)% change
Revenues ($M)$30,390-6.9%
Profits ($M)$13,501-25.4%
Assets ($M)$56,977-
Total Stockholder Equity ($M)$18,887-

Profit Ratios

Profit as % of Revenues44.4%
Profits as % of Assets23.7%
Profits as % of Stockholder Equity71.5%